Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxel
7035 Background: Second-line treatment for NSCLC patients (pts) with good performance status improves survival. Using the recent trial comparing survival with pemetrexed (500 mg/m2 q3wks) vs docetaxel (75 mg/m2 q3wks) we evaluated the benefit of second-line treatment in terms of palliation, and whether it occurs with less than a major response. Methods: 571 previously treated advanced NSCLC pts, randomized from 3/01 to 2/02, completed the Lung Cancer Symptom Scale (LCSS) which assesses quality of life and 6 symptoms with scores from 0 to 100. Analysis was performed on pts who had data from baseline and ≥1 treatment cycle. Pts were grouped by best overall response: complete or partial, or stable disease (CR/PR/SD) vs progressive disease (PD). A two-factor interaction model with treatment and tumor response as factors was used for analysis. Results: Baseline characteristics were well-balanced between treatment arms with 75% Stage IV and 88% ECOG PS 0/1. Survival time and response rate with pemetrexed were similar to docetaxel (median 8.3 vs 7.9 months [HR 0.99 (95% CI 0.82, 1.20)]; 9.1 vs 8.8%). SD rate was 46% for each arm. 484 pts were included in the LCSS analyses. Baseline LCSS scores were similar between arms. All within-arm improvements were significant except for hemoptysis in docetaxel arm; all between-arm comparisons were not. When pts with CR/PR were divided from those with SD and treatment groups were pooled, mean maximum improvement of Average Symptom Burden Index (average of 6 symptoms) was greater for those CR/PR than those with SD (9.9 vs 4.3); those with PD worsened (-3.7). Conclusions: We conclude that: 1) Symptomatic benefit is achieved in pts with advanced NSCLC receiving second-line single-agent chemotherapy; 2) Pts achieving tumor response or stable disease have a greater likelihood of pt-reported benefit than pts with progressive disease; and 3) Pemetrexed and docetaxel are similarly effective in palliating symptoms.